Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Monopar Therapeutics Inc.NASDAQ: MNPR
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares growth accelerates
Q1 FY2026 weighted avg shares of 8.54M shares rose 23.6% year over year, ahead of the -28.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 27.5% from the prior quarter. Over 3 fiscal years it compounded at -16.5% a year.
Context
- Weighted avg shares increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +23.6% holds above the trailing-twelve-month pace of -28.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 7.41M USD
- Year-over-year change
- -35.2%
- 4-year CAGR
- -12.2%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.41M | -35.2% |
| FY2024 | 2024-12-31 | 11.44M | -21.1% |
| FY2023 | 2023-12-31 | 14.51M | +14.1% |
| FY2022 | 2022-12-31 | 12.72M | +2.0% |
| FY2021 | 2021-12-31 | 12.47M | — |
Weighted Avg Shares vs competitors
How MNPR compares with its peers on the latest reported figures
- MNPR's LTM Mar 2026 weighted avg shares of 7.34M shares is the lowest of the 11 companies compared; the peer median is 74.3M shares.
- Its year-over-year change of -28.8% is the lowest of 11, against a peer median of +6.1%.
- Over three fiscal years its annual growth of -16.5% compares with a peer median of +9.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 161.95M | +17.8% | +14.5% | |
| LTM Mar 2026 | 138.66M | +34.3% | +17.6% | |
| LTM Sep 2026 | 106.83M | +34.8% | +93.1% | |
| FY2025 | 89.42M | +10.3% | +4.0% | |
| LTM Jun 2026 | 74.94M | +5.1% | +7.6% | |
| LTM Sep 2026 | 73.65M | -2.5% | +4.9% | |
| LTM Mar 2026 | 69.4M | +7.1% | +32.7% | |
| LTM Mar 2026 | 63.24M | +0.8% | +0.9% | |
| LTM Mar 2026 | 53.9M | +2.3% | +9.7% | |
| LTM Jun 2026 | 31.26M | +0.3% | +8.9% | |
| LTM Mar 2026 | 7.34M | -28.8% | -16.5% | |
| Peer median (excluding MNPR) | 74.3M | +6.1% | +9.3% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.49M | 7.59M | 5.6M | 13.01M | 9.9B |
| Selling, General & Admin | 2.63M | 2.95M | 3.23M | 3.16M | 6.8B |
| Operating Expenses | 9.13M | 10.54M | 8.83M | 16.16M | 16.7M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (9.13M) | (10.54M) | (8.83M) | (16.16M) | (16.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 24.02K | 21.24K | 429.04K | 404.02K | 2.99M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 24.02K | 21.24K | 429.04K | 575.3K | 2.99M |
| Income Before Tax | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.73) | (0.83) | (0.58) | (1.36) | (1.85) |
| EPS (Diluted) | (0.73) | (0.83) | (0.58) | (1.36) | (1.85) |
| Weighted Avg Shares | 12.47M | 12.72M | 14.51M | 11.44M | 7.41M |
| Weighted Avg Shares (Diluted) | 12.47M | 12.72M | 14.51M | 11.48M | 7.41M |
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.